

59-year-old female patient with lung cancer

This case was presented by Dr. Annarita Destro, Molecular Biologist at the Clinical Institute Humanitas in Milano, Italy.

THE SITUATION

- Needle lung biopsy revealed metastatic lung adenocarcinoma T2N2M1b (D7 rib metastasis).
- The number and percentage of tumor cells were greatly reduced (<100 and <10%, respectively) in the biopsy sample. A Sanger-based *EGFR* test was requested in March 2015, but a result could not be obtained due to lack of tumor material.

THE CHALLENGE

- As the general health condition of the patient was very poor, she could not be re-biopsied.

THE SOLUTION

- In May 2015, the lab acquired Agena Bioscience's MassARRAY® Dx technology and re-analyzed the small lung biopsy sample. *EGFR* test result with the Myriapod® Lung kit (Diatech Pharmacogenetics) on the MassARRAY Dx instrument (Agena Bioscience) revealed an E746_A750del ELREA.
- The entire analysis took less than 10 working days.
- Subsequently, the patient was treated with an TKI Inhibitor.
- Today the patient is in a stable disease state.

FURTHER BACKGROUND INFORMATION

- Before the introduction of the MassARRAY Dx technology, there was a 10% failure rate due to lack of material. After using the Myriapod kits and the MassARRAY Dx technology, this percentage decreased to 0%. Moreover, the workflow duration was significantly reduced using the MassARRAY Dx technology, with lower complexity and lower error probability.

Dr. Annarita Destro

*Molecular Biologist
at the Clinical Institute
Humanitas in Milano, Italy*

Learn more about MassARRAY Dx.

[http://agenabio.com/
products/massarray-dx/](http://agenabio.com/products/massarray-dx/)



Not available for sale
in the United States.